Table 3.
Cross-reactivity summary for Anti-CoV2*.
| Pathogen | N | Number cross-reactive | Number non-reactive |
|---|---|---|---|
| Adenovirus | 27 | 0 | 27 |
| Anti-nuclear antibody (ANA) | 5 | 0 | 5 |
| Bordetella pertussis | 27 | 0 | 27 |
| Chlamydia pneumoniae | 41 | 0 | 41 |
| Enterovirus | 20 | 0 | 20 |
| Haemophilus influenzae | 5 | 0 | 5 |
| HCoV 229E | 17 | 0 | 17 |
| HCoV HKU1 | 5 | 0 | 5 |
| HCoV NL63 | 5 | 0 | 5 |
| HCoV OC43 | 14 | 0 | 14 |
| Hepatitis B- HBc | 5 | 0 | 5 |
| Hepatitis B- HBs | 5 | 0 | 5 |
| Hepatitis C | 5 | 0 | 5 |
| Influenza A | 68 | 0 | 68 |
| Influenza B | 72 | 0 | 72 |
| Legionella pneumophila | 12 | 0 | 12 |
| Mycoplasma pneumoniae | 77 | 0 | 77 |
| Parainfluenza virus | 99 | 0 | 99 |
| Respiratory syncytial virus | 81 | 0 | 81 |
ANA, anti-nuclear antibody; HBc, hepatitis B core antibody; HBs, hepatitis B surface antibody; HCoV, human coronavirus.
*
Cross reactivity is evaluated separately for each pathogen category. Several specimens contained antibodies to multiple pathogens, resulting in some specimens listed more than once, but in separate pathogen categories.